CRISPR’s promise, biotech lottery tickets, and the future of VC

Those are just a few of the topics our very own Matthew Herper and Adam Feuerstein discussed in an AMA-style chat yesterday, one that touched on Biogen’s predicament, the utility of gene therapy, and the immortal question of biotech M&A.

If you missed the chat, you missed Adam weighing in on Sangamo Therapeutics, Matt discussing the prospects for Amarin, and a treatise on companies calling themselves “the next Genentech.” Luckily, we archived the whole thing, and STAT Plus subscribers can find it right here.